SC Therapeutics launches REACH2 as SC0032 targets chronic cough beyond symptom control
SC Therapeutics is advancing an unconventional soft-mist spray into a more rigorous UK study designed to test objective cough reduction, durability and the limits of an upstream airway-focused mechanism.